MOLECULAR MEDICINE REPORTS  16:  9270,  2017

CORRIGENDUM 

DOI: 10.3892/mmr.2017.7698

Farnesoid X receptor deletion improves cardiac function, 
structure and remodeling following myocardial infarction 
in mice

JIANSHU GAO, XIAOQIANG LIU3, BINGJIAN WANG, HAIYAN 
XU, QIANG XIA, TIANFEI LU and FANG WANG 

Mol Med Rep 16: 673-679, 2017; DOI: 10.3892/mmr.2017.6643

Following the publication of this article, an interested reader 
drew to our attention that we had incorrectly reported (in the 
Materials and methods section, ‘Western blot analysis’, on 
p. 674) that the anti-farnesoid X receptor (FXR) antibody of 
Cell Signalling Technology, Inc., cat. no. #12295, had been 
used in this study to probe for FXR. In fact, the antibodies 
used in the above-mentioned study were a gift from the group 
of Dr Xin-Liang Ma at Thomas Jefferson University 
(Philadelphia, PA, USA), as referenced in the following article: 
[Pul J, Yuan A, Shan P, Gao E, Wang X, Wang Y, Lau WB, 
Koch W, Xin-Ma XL and He B: Cardiomyocyte-expressed 
farnesoid-X-receptor is a novel apoptosis mediator and 
contributes to myocardial ischaemia/reperfusion injury. Eur 
Heart J 34: 1834-1845,  2013]. The antibody that was used for 
the western blotting analysis was raised against the C-terminus 
of FXR (C-20; cat. no. sc-1204, Santa Cruz Biotechnology, San 
Diego, CA, USA).

We sincerely apologize for this mistake, and thank the 
reader of our article who drew this matter to our attention. The 
error made in our incorrect referencing of the antibody did not 
affect the conclusions reported in this study. Furthermore, we 
regret the inconvenience that this mistake caused.